4793-22-0

Basic information

• Product Name: 4-Chloro-2-fluoro-5-sulfamylbenzoic acid
• Synonyms: 4-CHLORO-2-FLUORO-5-SULFAMOYLBENZOIC ACID;4-CHLORO-2-FLUORO-5-SULFAMYLBENZOIC ACID;2-FLUORO-4-CHLORO-5-SULFAMOYL BENZOIC ACID;5-(Aminosulfonyl)-4-chloro-2-fluorobenzoic acid;4-Chloro-2-fluoro-5-;Benzoic acid,5-(aMinosulfonyl)-4-chloro-2-fluoro-
• CAS NO: 4793-22-0
• Molecular Formula: C₇H₅ClFNO₄S
• Molecular Weight: 253.64
• Product Categories: API intermediates
• Mol File: 4793-22-0.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 474.756 °C at 760 mmHg
• Flash Point: 240.924 °C
• Appearance: /
• Density: 1.725 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.601
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-Chloro-2-fluoro-5-sulfamylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-2-fluoro-5-sulfamylbenzoic acid(4793-22-0)
• EPA Substance Registry System: 4-Chloro-2-fluoro-5-sulfamylbenzoic acid(4793-22-0)

Safety Data

• Hazardous Substances Data: 4793-22-0(Hazardous Substances Data)

Usage

Description

4-Chloro-2-fluoro-5-sulfamylbenzoic acid is a sulfonamide derivative with the molecular formula C7H6ClFNO4S. It is characterized by the presence of both a chloro and a fluoro substituent on the benzene ring, which enhances its antimicrobial activity. This chemical compound is known for its effectiveness as a sulfonamide antibiotic, targeting a broad spectrum of gram-positive and gram-negative bacteria by inhibiting their folic acid synthesis, a process crucial for bacterial growth and replication.

Uses

Used in Pharmaceutical Industry:
4-Chloro-2-fluoro-5-sulfamylbenzoic acid is used as a sulfonamide antibiotic for its broad-spectrum antibacterial activity. It is particularly effective against a wide range of gram-positive and gram-negative bacteria due to its ability to inhibit the synthesis of bacterial folic acid, which is essential for their growth and replication.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-Chloro-2-fluoro-5-sulfamylbenzoic acid serves as a valuable compound for the development of new antibiotics and antimicrobial agents. Its unique structure with chloro and fluoro substituents offers a promising platform for designing innovative therapeutic agents to combat bacterial infections, especially in the context of increasing antibiotic resistance.

InChI:InChI=1/C7H5ClFNO4S/c8-4-2-5(9)3(7(11)12)1-6(4)15(10,13)14/h1-2H,(H,11,12)(H2,10,13,14)

Upstream product

• 56447-54-2 4-chloro-2-fluoro-5-chlorosulfonylbenzoic acid 
• 446-30-0 4-chloro-2-fluorobenzoic acid 

Downstream Products

• 54-31-9 4-chloro-2-furfurylamino-5-sulfamoyl-benzoic acid 
• 716356-31-9 C₃₅H₃₈ClF₂N₅O₃S 

Relevant articles and documents

Design, synthesis, and biological evaluation of furosemide analogs as therapeutics for the proteopathy and immunopathy of Alzheimer's disease

β-Amyloid (Aβ) triggered proteopathic and immunopathic processes are a postulated cause of Alzheimer's disease (AD). Monomeric Aβ is derived from amyloid precursor protein, whereupon it aggregates into various assemblies, including oligomers and fibrils, which disrupt neuronal membrane integrity and induce cellular damage. Aβ is directly neurotoxic/synaptotoxic, but may also induce neuroinflammation through the concomitant activation of microglia. Previously, we have shown that furosemide is a known anthranilate-based drug with the capacity to downregulate the proinflammatory microglial M1 phenotype and upregulate the anti-inflammatory M2 phenotype. To further explore the pharmacologic effects of furosemide, this study reports a series of furosemide analogs that target both Aβ aggregation and neuroinflammation, thereby addressing the combined proteopathic-immunopathic pathogenesis of AD. Forty compounds were synthesized and evaluated. Compounds 3c, 3g, and 20 inhibited Aβ oligomerization; 33 and 34 inhibited Aβ fibrillization. 3g and 34 inhibited the production of TNF-α, IL-6, and nitric oxide, downregulated the expression of COX-2 and iNOS, and promoted microglial phagocytotic activity, suggesting dual activity against Aβ aggregation and neuroinflammation. Our data demonstrate the potential therapeutic utility of the furosemide-like anthranilate platform in the development of drug-like molecules targeting both the proteopathy and immunopathy of AD.

Synthetic method of Azosemide intermediate

The invention discloses a synthesis method of an azeosemide intermediate, wherein the synthesis method comprises the following steps: (1) catalytic sulfonation reaction: carrying out catalytic sulfonation reaction on 4-chloro-2-fluorobenzoic acid and chlo

IL-8 RECEPTOR ANTAGONISTS

This invention relates to novel compounds, compositions and combinations thereof, useful in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).